Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

Presentation AHA 2022

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Presenter: Gregg W. Stone

November 07, 2022

Presentation ESC 2017

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Presenter: David Erlinge

August 27, 2017

Presentation

Primary PCI Outcomes in STEMI Patients Treated via Radial Access With Bivalirudin or Heparin

May 23, 2017

Presentation

BRIGHT: Bivalirudin vs Heparin With or Without Tirofiban During Primary PCI in Acute MI

Presenter: Yaling Han

March 23, 2015

Presentation

Bivalirudin vs Heparin With or Without GPIs in Patients With STEMI Undergoing Primary PCI

Presenter: Gregg W. Stone

January 05, 2015

Presentation TCT 2014

Con: Follow the Data and Save the Patient!

Presenter: Adrian P. Banning, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

Pro: Follow the Data - and Save the Money!

Presenter: Adrian P. Banning, Rod H. Stables

September 16, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention

Presenter: Ahmed Rehmani

September 16, 2014

Presentation TCT 2014

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

Presenter: John A. Bittl, Tullio Palmerini, Salvatore Cassese, MD

September 15, 2014

Presentation TCT 2014

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

Presenter: Roxana Mehran, Harvey D. White, Yaling Han

September 15, 2014

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Rod H. Stables

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Gregg W. Stone

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Heparin!

Presenter: Stefanie Schüpke

September 14, 2014

Presentation TCT 2014

The Data Strongly Support Bivalirudin!

Presenter: Roxana Mehran

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation

Bivalirudin vs Heparin in Patients Planned for PCI

Presenter: Matthew A. Cavender

August 20, 2014

$Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial$

Presentation

Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial

Presenter: A. Shahzad

July 10, 2014

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

Advertisement

Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Primary PCI Outcomes in STEMI Patients Treated via Radial Access With Bivalirudin or Heparin

BRIGHT: Bivalirudin vs Heparin With or Without Tirofiban During Primary PCI in Acute MI

Bivalirudin vs Heparin With or Without GPIs in Patients With STEMI Undergoing Primary PCI

Con: Follow the Data and Save the Patient!

Pro: Follow the Data - and Save the Money!

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention

TCT 460: Bivalirudin Versus Heparin During Percutaneous Coronary Intervention: A Meta-analysis of Randomized Trials

BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

The Data Strongly Support Heparin!

The Data Strongly Support Bivalirudin!

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Bivalirudin vs Heparin in Patients Planned for PCI

Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content